Trained Immunity Recasts How Dendritic Cells and Macrophages Drive Allergy
Trained immunity is changing how immunology frames the behavior of dendritic cells and macrophages in allergic disease. Rather than acting as static sentinels, these antigen-presenting cells can adopt durable functional states after microbial exposure, vaccination, or other immune stimuli, with downstream effects on how they process and present antigen. In allergic disease, that persistence matters because the same cells help shape whether the immune response tilts toward tolerance, inflammation, or a type 2 profile that promotes clinical allergy.
The review ties this biology to a practical clinical question: why do some patients appear primed toward allergic disease early in life, while others respond differently to allergen exposure and immunotherapy later on? The answer appears to involve not only receptor signaling, but also cell metabolism. Activated dendritic cell subsets and classically activated M1 macrophages increase glycolysis and show a disrupted Krebs cycle, a metabolic pattern suited to rapid effector activity and inflammatory mediator production. By contrast, alternatively activated M2 macrophages, plasmacytoid dendritic cells, and conventional dendritic cells type 1 rely more heavily on oxidative phosphorylation for their effector functions.
Metabolic Reprogramming as an Immune Decision Point
The metabolic switch is not cosmetic. It helps determine what these cells can do, how long they remain active, and which immune signals they amplify. Glycolysis supports rapid energy generation and biosynthetic demands during inflammation, while oxidative phosphorylation tends to fit more regulated or specialized cellular programs. In that sense, immune metabolism functions as part of the decision architecture of allergy: the same APC compartment can either reinforce a Th2-skewed environment or participate in immune modulation that tempers it.
For allergists and immunologists, this creates a more layered model of disease. Allergy is not explained solely by IgE or effector-cell activation. It also depends on the programming state of the upstream cells that present antigen and instruct T-cell responses. The review places dendritic cells and macrophages at the center of that process, especially because their trained states may persist long enough to influence repeated exposures over time.
A persistent cellular memory can amplify allergic bias long after the initial trigger has passed.
Early-Life Infections, Allergic Predisposition, and APC Memory
One of the most clinically intriguing ideas in the review is the suggestion that infections early in life may predispose children to later allergy through trained immunity mechanisms. This does not mean infection directly causes allergy in a simple linear way. Instead, it suggests that immune exposures during critical developmental windows may leave a lasting imprint on APC function, shifting how dendritic cells and macrophages respond to later antigen encounters.
That concept fits with the broader observation that allergic children may exhibit distinct trained immunity responses. The review does not claim a single biomarker already defines this state, but it argues that immune-metabolic alterations in APCs could eventually help explain why some pediatric patients move toward chronic allergic disease. The biological plausibility is strong: if the cells responsible for antigen presentation are reprogrammed early, subsequent exposures can be interpreted through that altered lens.
This is especially relevant because allergy often emerges over years, not in a single event. The developmental trajectory matters. Early-life immune education, environmental exposures, and microbial signals may all shape the phenotype that later becomes visible in the clinic as rhinitis, asthma, food allergy, or other atopic disease.
Allergen-Specific Immunotherapy and the Possibility of Reprogramming
The review also addresses allergen-specific immunotherapy, where immune modulation is a therapeutic goal rather than an incidental effect. Here, trained immunity may contribute to the shift observed during treatment. If APCs can be metabolically and functionally re-educated, then immunotherapy may work partly by changing how these cells respond to allergen exposure over time.
This framing is useful because it moves beyond a narrow view of immunotherapy as antigen desensitization alone. It suggests that successful treatment may involve deeper changes in dendritic cell and macrophage behavior, including altered inflammatory tone and modified T-cell instruction. For patients, that may translate into improved control of allergic symptoms and a more durable therapeutic response, though the review stops short of presenting a validated clinical assay for routine use.
The review’s clinical implication is straightforward: if trained immunity shapes treatment response, then it may also help explain heterogeneity in who benefits most from immunotherapy, who responds more slowly, and who remains refractory. Those are the questions that matter in day-to-day allergy care, where broad disease labels often conceal substantial biological diversity.
Biomarkers, Targeted Therapy, and the Unfinished Translational Gap
A major promise of this area lies in biomarker development. Better understanding of trained immunity in dendritic cells and macrophages could support more targeted and efficient treatment of allergic diseases. The appeal is obvious: biomarkers tied to APC metabolic state or trained immune programming might eventually help stratify patients before treatment begins, identify those most likely to benefit from immunotherapy, or track immune reprogramming during therapy.
Still, the field remains at an early mechanistic stage. The review summarizes current knowledge rather than presenting a definitive therapeutic algorithm. It does not establish which biomarker is ready for clinical deployment, nor does it claim that APC metabolism can yet be manipulated in routine practice to improve allergy outcomes. What it does provide is a coherent mechanistic bridge between innate immune memory and allergic disease expression.
That bridge matters because it links biology with bedside consequences. If dendritic cells and macrophages are not merely passive intermediaries but durable participants in allergic programming, then future treatment strategies may need to account for immune memory at the level of the innate system, not just the adaptive one. For clinicians, that could eventually reshape how allergy risk is assessed, how pediatric predisposition is interpreted, and how immunotherapy is tailored to individual immune states.
The current evidence is still incomplete, and the review leaves open the central translational challenge: which trained immunity signatures are reproducible enough to guide care, and which remain confined to experimental models? Until those questions are answered, the most defensible conclusion is mechanistic rather than procedural — trained immunity in dendritic cells and macrophages appears to be part of the biology of allergic disease, but its clinical utility will depend on whether those immune states can be measured and modified with precision.